Synopsys Up Over 10%, on Pace for Record High Close — Data Talk
Synopsys, Inc. (SNPS) is currently at $599.27, up $55.70 or 10.25%
--Would be new all-time high (Based on available data back to Feb. 26, 1992)
--On pace for largest percent increase since May 19, 2022, when it rose 10.25%
--Snaps a four day losing streak
--Up 12.36% month-to-date
--Up 16.38% year-to-date
--Up 63.97% from 52 weeks ago (Feb. 23, 2023), when it closed at $365.48
--Would be a new 52-week closing high
--Up 68.7% from its 52-week closing low of $355.23 on March 10, 2023
--Traded as high as $629.38; new all-time intraday high (Based on available data back to Feb. 26, 1992)
--Up 15.79% at today's intraday high; largest intraday percent increase since Dec. 4, 2008, when it rose as much as 20.48%
--Second best performer in the S&P 500 today
--Second best performer in the Nasdaq 100 today
All data as of 9:57:56 AM ET
Source: Dow Jones Market Data, FactSet
(END) Dow Jones Newswires
February 22, 2024 10:15 ET (15:15 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
What’s the Difference Between the CPI and PCE Indexes?
-
Micron Earnings: Great Guidance but Stock Now Looks Fairly Valued
-
August PCE Report Forecasts Show More Good News on Inflation
-
AI Stocks May Be Down, but Don’t Count Them Out
-
4 Stocks to Buy as the Fed Cuts Interest Rates
-
Markets Brief: The Uncertain Path to Neutral Interest Rates
-
What’s Happening in the Markets This Week
-
Where Top Stock Fund Managers Are Looking Next After the Fed Rate Cut
-
Our Top Pick for Investing in US Renewable Energy
-
How to Measure a Stock’s Uncertainty
-
How to Determine Whether a Stock Is Cheap, Expensive, or Fairly Valued
-
Why a Company’s Management and Capital Allocation Matter
-
How to Determine What a Stock Is Worth
-
How to Measure a Company’s Competitive Advantage
-
How to Think Like a Stock Analyst
-
How GLP-1 Drugs Like Ozempic Are Boosting Biopharma Stocks